Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04021862 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis and Eczema, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 17
- Study locations
NCT04021862 is a Phase 2 study of Atopic Dermatitis and Eczema that has completed, run by Janssen Research & Development. The registered enrollment target is 87 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (86% lower). The trial reports 17 study locations across 9 states.
The verdict
NCT04021862, a Phase 2 study of Atopic Dermatitis and Eczema, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 17
- Study locations
Study Summary
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bermekimab Monoclonal Antibody
Study Locations (17)
Florida
- Florida Academic Dermatology Centers - Coral Gables
- Doral Medical Research - Doral
- Floridian Research Institute - Miami
- Florida International Medical Research - Miami
- Premier Research Associate, Inc - Miami
- CNS HealthCare - Orlando
- Avita Clinical Research - Tampa
- Forcare Clinical Research Inc - Tampa
Indiana
- Dawes Fretzin Clinical Research Group - Indianapolis
- Randall Dermatology & Cosmetic Surgery - West Lafayette
California
- Beach Clinical Research Inc - Huntington Beach
Georgia
- Advanced Medical Research - Sandy Springs
Michigan
- Revival Research Institute LLC - Troy
Ohio
- ClinOhio Research Services - Columbus
Tennessee
- Helios Clinical Research, LLC - Milan
Texas
- Progressive Clinical Research - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2019-10-16 |
| Est. Completion | 2020-11-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04021862
The ClinicalTrials.gov registry entry for NCT04021862 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (86% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04021862 reports 17 study locations spanning 9 distinct geographic areas - top geographies include Florida, Indiana, California.
Frequently Asked Questions
What is clinical trial NCT04021862 about?
NCT04021862 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis". A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
What is the current status of trial NCT04021862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2019-10-16. Estimated completion is 2020-11-19.
What conditions does trial NCT04021862 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema.
What interventions are being tested in trial NCT04021862?
The interventions under investigation include: Placebo (DRUG), Bermekimab Monoclonal Antibody (DRUG).
Who is sponsoring clinical trial NCT04021862?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04021862 being conducted?
This trial has 17 study locations across California, Florida, Georgia, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.